gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IBRXHealthcareBiotechnology

ImmunityBio, Inc. Common Stock (IBRX)

$8.93+7.72%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$8.29▲ 266.81% in range
Nov 3, 2025Low $1.98 · High $11.55Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

ImmunityBio closed at $8.93 on Nov 4, up 7.72%, 22.7% below its 52-week closing high. Volume of 9.7M shares was 0.75× its 20-day average (below normal).

Split-adjusted performance: -7.8% over one month, +6.6% over six months, +295.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $51.24M, up 93.9% from a year earlier, with a net margin of -449.6%.

Short interest was 122.9M shares at the Oct 15 settlement (31.2% of float, 7.2 days to cover).

Market cap$9.46B1.06B shares
Revenue · quarter$51.2M+93.9% YoY
Diluted EPS$-0.22—
P/E · TTM—P/S 57.1×
Net margin-449.6%Gross 99.4%
Dividend yieldNone
52-week range1.98 – 11.55−22.7% from high
Volume9.7M0.75× 20-day avg
Volatility · 60d70.0%Annualised
Short % of float31.2%7.2 days to cover
Net cash-$57.7MCash $357.4M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.4%1M −7.8%3M +22.0%6M +6.6%YTD +351.0%1Y +295.1%3Y +189.9%5Y +14.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum70
Revenue growth84
Net margin44
Value (low P/E)—
Size91

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short122.9M−0.9% vs prior
Days to cover7.2Settled Oct 15
% of float31.2%
Short vol. 10d59.7%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IBRXImmunityBio$8.93+7.72%+6.6%+93.9%−449.6%—$9.46B
TWSTTwist Bioscience$142.58+1.63%+139.5%+23.2%−29.6%—$9.45BCompare
KRYSKrystal Biotech$310.84+1.90%+7.6%+30.2%49.5%40.9$9.20BCompare
PCVXVaxcyte$65.68+8.01%+15.0%———$10.34BCompare
RGENRepligen$178.20−0.04%+41.7%+10.9%−18.4%—$11.31BCompare
TECHBio-Techne$72.73+0.10%+53.4%+1.3%17.0%62.8$11.42BCompare
KYMRKymera Therapeutics$136.25+7.21%+58.0%−100.0%——$11.63BCompare
KODKodiak Sciences$98.51−0.38%+114.7%———$6.19BCompare
IMVTImmunovant$29.90+2.96%+4.3%———$6.18BCompare

News about ImmunityBio

All news →
FDA Expands ImmunityBio's Anktiva Label in Bladder CancerZacks Investment Research · Oct 15, 2026▲ PositiveINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRXGlobeNewswire Inc. · May 26, 2026▼ NegativeIBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewswire Inc. · May 25, 2026▼ NegativeIBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc. · May 25, 2026▼ NegativeIBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRXGlobeNewswire Inc. · May 22, 2026▼ Negative

Quick answers

What does ImmunityBio do?
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform.
What is IBRX's market cap?
$9.46B, based on the Nov 4 close of $8.93.
Does ImmunityBio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IBRX is sold short?
122.9M shares, 31.2% of float, as of Oct 15, 2026.
What sector is IBRX in?
Healthcare, in the Biotechnology industry.

About ImmunityBio

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

HQ: San Diego, CA691 employeesListed Mar 10, 2021immunitybio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology